NANTES, France, May 29, 2012 /PRNewswire-iReach/ -- Grant of a major patent from the European

NEWARK, Del., April 10, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) announced that its proprietary iBioLaunch(TM) technology for the production of biotherapeutic proteins and vaccine

TORONTO, April 4, 2012 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company developing proprietary and innovative biologic therapies, today provided an update

Company to present data on new designer cell lines metabolically engineered to overcome the specific expression bottlenecks associated with difficult-to-express proteins. Geneva,

About 15 percent of cases of an aggressive, difficult-to-detect form of ovarian cancer contain a unique fusion between two neighboring, normally separate genes, say researchers at the Stanford University School of Medicine.